Panzyga

Phase 3Small molecule

Panzyga is one of 6 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Chronic Inflammatory Demyelinating Polyneuropathy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

2 2

Vyvgart

Argenx

Phase 2

2 3

Empasiprubart

Argenx

Phase 3

2 4

Ripertamab

ZZhongming Qiu

Phase 3

1 5

Panzyga

Octapharma

Phase 3

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT04929236

Clinical

Trials by Indication[1]

Efficacy1 trial

Non-Interventional Study on the Tolerability and Efficacy of IVIG

Completed· Octapharma logo

Octapharma··NCT02303093·344 enrolled

Pediatric1 trial

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Completed· Octapharma logo

Octapharma·Phase 3·NCT04508530·71 enrolled

Immune Thrombocytopenia1 trial

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Terminated· Octapharma logo

Octapharma·Phase 4·NCT03866798·6 enrolled

Chronic Lymphocytic Leukemia1 trial

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Completed· Octapharma logo

Octapharma·Phase 3·NCT04502030·247 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Recruiting· Octapharma logo

Octapharma·Phase 3·NCT04929236·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Panzyga. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Panzyga compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Panzyga. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Panzyga

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Efficacy1 trial

Pediatric1 trial

Immune Thrombocytopenia1 trial

Chronic Lymphocytic Leukemia1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News